The Pharmacy Board of Australia
says it’s worried about the
ramifications for pharmacists in
relation to the decision by the
Administrative Appeals Tribunal in
favour of Aspen Pharmaceuticals
which has allowed medications
containing dextropropoxyphene to
remain on the market.
According to the ruling, amongst
other things, Aspen must enter into
contracts with pharmacists (other
than hospital pharmacists) who
wish to continue to supply Di-Gesic
and Doloxene.
Aspen is required to write to
pharmacies setting out in detail
the obligations that pharmacists
must comply with if they wish to
continue dispensing the products.
The Board noted the decision
with concern, given that products
containing dextropropoxyphene
have been removed from the
market by medicine regulators in a
number of countries,” according to
a Board communiqué last Fri.The above article was sent to subscribers in Pharmacy Daily's issue from 08 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Oct 13
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
THE Pharmaceutical Society of Australia (PSA) has unveiled a comprehensive membership package designed to provide robust support for credentialed pharmacists throughout their professional journey.
MEDICAL research produces better outcomes when people with lived experience are involved in the process, according to Breast Cancer Network Australia (BCNA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.